Literature DB >> 33554860

shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data.

Kenichi Shimada1, John A Bachman1, Jeremy L Muhlich1, Timothy J Mitchison1.   

Abstract

Individual cancers rely on distinct essential genes for their survival. The Cancer Dependency Map (DepMap) is an ongoing project to uncover these gene dependencies in hundreds of cancer cell lines. To make this drug discovery resource more accessible to the scientific community, we built an easy-to-use browser, shinyDepMap (https://labsyspharm.shinyapps.io/depmap). shinyDepMap combines CRISPR and shRNA data to determine, for each gene, the growth reduction caused by knockout/knockdown and the selectivity of this effect across cell lines. The tool also clusters genes with similar dependencies, revealing functional relationships. shinyDepMap can be used to (1) predict the efficacy and selectivity of drugs targeting particular genes; (2) identify maximally sensitive cell lines for testing a drug; (3) target hop, that is, navigate from an undruggable protein with the desired selectivity profile, such as an activated oncogene, to more druggable targets with a similar profile; and (4) identify novel pathways driving cancer cell growth and survival.
© 2021, Shimada et al.

Entities:  

Keywords:  DepMap; cancer biology; computational biology; essential genes; human; precision medicine; selectivity; shinyDepMap; synthetic lethality; systems biology

Mesh:

Substances:

Year:  2021        PMID: 33554860      PMCID: PMC7924953          DOI: 10.7554/eLife.57116

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  27 in total

1.  Remarkable conservation of translation initiation factors: IF1/eIF1A and IF2/eIF5B are universally distributed phylogenetic markers.

Authors:  H P Sørensen; J Hedegaard; H U Sperling-Petersen; K K Mortensen
Journal:  IUBMB Life       Date:  2001-05       Impact factor: 3.885

2.  Defining a Cancer Dependency Map.

Authors:  Aviad Tsherniak; Francisca Vazquez; Phil G Montgomery; Barbara A Weir; Gregory Kryukov; Glenn S Cowley; Stanley Gill; William F Harrington; Sasha Pantel; John M Krill-Burger; Robin M Meyers; Levi Ali; Amy Goodale; Yenarae Lee; Guozhi Jiang; Jessica Hsiao; William F J Gerath; Sara Howell; Erin Merkel; Mahmoud Ghandi; Levi A Garraway; David E Root; Todd R Golub; Jesse S Boehm; William C Hahn
Journal:  Cell       Date:  2017-07-27       Impact factor: 41.582

3.  Comprehensive Characterization of Cancer Driver Genes and Mutations.

Authors:  Matthew H Bailey; Collin Tokheim; Eduard Porta-Pardo; Sohini Sengupta; Denis Bertrand; Amila Weerasinghe; Antonio Colaprico; Michael C Wendl; Jaegil Kim; Brendan Reardon; Patrick Kwok-Shing Ng; Kang Jin Jeong; Song Cao; Zixing Wang; Jianjiong Gao; Qingsong Gao; Fang Wang; Eric Minwei Liu; Loris Mularoni; Carlota Rubio-Perez; Niranjan Nagarajan; Isidro Cortés-Ciriano; Daniel Cui Zhou; Wen-Wei Liang; Julian M Hess; Venkata D Yellapantula; David Tamborero; Abel Gonzalez-Perez; Chayaporn Suphavilai; Jia Yu Ko; Ekta Khurana; Peter J Park; Eliezer M Van Allen; Han Liang; Michael S Lawrence; Adam Godzik; Nuria Lopez-Bigas; Josh Stuart; David Wheeler; Gad Getz; Ken Chen; Alexander J Lazar; Gordon B Mills; Rachel Karchin; Li Ding
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

4.  Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.

Authors:  Rita Sulahian; Jason J Kwon; Katherine H Walsh; Emma Pailler; Timothy L Bosse; Maneesha Thaker; Diego Almanza; Joshua M Dempster; Joshua Pan; Federica Piccioni; Nancy Dumont; Alfredo Gonzalez; Jonathan Rennhack; Behnam Nabet; John A Bachman; Amy Goodale; Yenarae Lee; Mukta Bagul; Rosy Liao; Adrija Navarro; Tina L Yuan; Raymond W S Ng; Srivatsan Raghavan; Nathanael S Gray; Aviad Tsherniak; Francisca Vazquez; David E Root; Ari J Firestone; Jeff Settleman; William C Hahn; Andrew J Aguirre
Journal:  Cell Rep       Date:  2019-10-01       Impact factor: 9.423

5.  Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy.

Authors:  Yong Wang; Virginia Probin; Daohong Zhou
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

Review 6.  The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus.

Authors:  Tianru Jin; Ling Liu
Journal:  Mol Endocrinol       Date:  2008-07-03

7.  Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.

Authors:  Robin M Meyers; Jordan G Bryan; James M McFarland; Barbara A Weir; Ann E Sizemore; Han Xu; Neekesh V Dharia; Phillip G Montgomery; Glenn S Cowley; Sasha Pantel; Amy Goodale; Yenarae Lee; Levi D Ali; Guozhi Jiang; Rakela Lubonja; William F Harrington; Matthew Strickland; Ting Wu; Derek C Hawes; Victor A Zhivich; Meghan R Wyatt; Zohra Kalani; Jaime J Chang; Michael Okamoto; Kimberly Stegmaier; Todd R Golub; Jesse S Boehm; Francisca Vazquez; David E Root; William C Hahn; Aviad Tsherniak
Journal:  Nat Genet       Date:  2017-10-30       Impact factor: 38.330

8.  The Cullin-3-Rbx1-KCTD10 complex controls endothelial barrier function via K63 ubiquitination of RhoB.

Authors:  Igor Kovačević; Tomohisa Sakaue; Jisca Majoleé; Manon C Pronk; Masashi Maekawa; Dirk Geerts; Mar Fernandez-Borja; Shigeki Higashiyama; Peter L Hordijk
Journal:  J Cell Biol       Date:  2018-01-22       Impact factor: 10.539

9.  Combined gene essentiality scoring improves the prediction of cancer dependency maps.

Authors:  Wenyu Wang; Alina Malyutina; Alberto Pessia; Jani Saarela; Caroline A Heckman; Jing Tang
Journal:  EBioMedicine       Date:  2019-11-12       Impact factor: 8.143

10.  Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration.

Authors:  James M McFarland; Zandra V Ho; Guillaume Kugener; Joshua M Dempster; Phillip G Montgomery; Jordan G Bryan; John M Krill-Burger; Thomas M Green; Francisca Vazquez; Jesse S Boehm; Todd R Golub; William C Hahn; David E Root; Aviad Tsherniak
Journal:  Nat Commun       Date:  2018-11-02       Impact factor: 14.919

View more
  8 in total

Review 1.  Hidden codes in mRNA: Control of gene expression by m6A.

Authors:  Shino Murakami; Samie R Jaffrey
Journal:  Mol Cell       Date:  2022-06-16       Impact factor: 19.328

Review 2.  A framework for fibrolamellar carcinoma research and clinical trials.

Authors:  Timothy A Dinh; Alan F Utria; Kevin C Barry; Rosanna Ma; Ghassan K Abou-Alfa; John D Gordan; Elizabeth M Jaffee; John D Scott; Jessica Zucman-Rossi; Allison F O'Neill; Mark E Furth; Praveen Sethupathy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-21       Impact factor: 73.082

3.  DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets.

Authors:  Alyssa Obermayer; Li Dong; Qianqian Hu; Michael Golden; Jerald D Noble; Paulo Rodriguez; Timothy J Robinson; Mingxiang Teng; Aik-Choon Tan; Timothy I Shaw
Journal:  Biology (Basel)       Date:  2022-02-08

4.  Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry.

Authors:  Feng Li; Li Lai; Zhijie You; Hui Cheng; Guodong Guo; Chenchen Tang; Luyun Xu; Hongxia Liu; Wenting Zhong; Youyu Lin; Qingshui Wang; Yao Lin; Yongbao Wei
Journal:  Front Mol Biosci       Date:  2022-02-08

5.  Pan-cancer analysis of non-oncogene addiction to DNA repair.

Authors:  Luis Bermúdez-Guzmán
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

6.  Exploiting gene dependency to inform drug development for multiple myeloma.

Authors:  Molly Went; Phuc H Hoang; Philip J Law; Martin F Kaiser; Richard S Houlston
Journal:  Sci Rep       Date:  2022-07-26       Impact factor: 4.996

7.  EZCancerTarget: an open-access drug repurposing and data-collection tool to enhance target validation and optimize international research efforts against highly progressive cancers.

Authors:  David Dora; Timea Dora; Gabor Szegvari; Csongor Gerdán; Zoltan Lohinai
Journal:  BioData Min       Date:  2022-10-01       Impact factor: 4.079

8.  A pan-CRISPR analysis of mammalian cell specificity identifies ultra-compact sgRNA subsets for genome-scale experiments.

Authors:  Boyang Zhao; Yiyun Rao; Scott Leighow; Edward P O'Brien; Luke Gilbert; Justin R Pritchard
Journal:  Nat Commun       Date:  2022-02-02       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.